Evidence map›Paper›PMID 38544938›Full record

ArticleRSC advances2024

Yan Peng, Mengqi Li, Fuyu Gong, Xiaofei Liu, Jirou Xiong, Keran Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Imaging methods to monitor and quantify cell differentiation.Frontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yan PengThe Affiliated First Hospital of Fuyang Normal University, Fuyang Normal University Fuyang Anhui 236037 P.R. China pengyan@fynu.edu.cn gong2022@fynu.edu.cn.ORCID https://orcid.org/0000-0001-6086-0609
Mengqi LiThe Affiliated First Hospital of Fuyang Normal University, Fuyang Normal University Fuyang Anhui 236037 P.R. China pengyan@fynu.edu.cn gong2022@fynu.edu.cn.
Fuyu GongThe Affiliated First Hospital of Fuyang Normal University, Fuyang Normal University Fuyang Anhui 236037 P.R. China pengyan@fynu.edu.cn gong2022@fynu.edu.cn.
Xiaofei LiuThe Affiliated First Hospital of Fuyang Normal University, Fuyang Normal University Fuyang Anhui 236037 P.R. China pengyan@fynu.edu.cn gong2022@fynu.edu.cn.
Jirou XiongThe Affiliated First Hospital of Fuyang Normal University, Fuyang Normal University Fuyang Anhui 236037 P.R. China pengyan@fynu.edu.cn gong2022@fynu.edu.cn.
Keran WangThe Affiliated First Hospital of Fuyang Normal University, Fuyang Normal University Fuyang Anhui 236037 P.R. China pengyan@fynu.edu.cn gong2022@fynu.edu.cn.
Fuyang Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Messenger RNA (mRNA) is an essential component of cell development and growth. However, the detection of endogenous mRNA in living cells is currently limited. To address this issue, we have developed a novel strategy that comprises split-aptamer and split fluorescent protein dual-color, "turn-on" probes that specifically target mRNA with complementary sequences. Our split-aptamer and split-protein-initiated fluorescence complementation (sAPiFC) approach for live-cell imaging has demonstrated selectivity, stability, and capability for targeting various mRNAs.

Identifiers

PMID38544938
PMCPMC10964932
OpenAlexW4393206686

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.